CompletedNot Applicable

Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients

France257 participantsStarted 2018-01-19

Plain-language summary

ECMO has improved the outcome of heart or respiratory failure and carcinogenic shock and are increasingly used. However bleeding complications occurring in up to 50% of patients are poorly understood and worsen the overall results. The aim is to investigate the occurence of bleeding and its frequency according to the type of ECMO either veno-arterial or veno-venous. The investigators also want to assess the relation of bleeding with von Willebrand Factor defects.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * informed consent of patient or person in charge * patient supplied by an ECMO for cardiac or respiratory failure and referred to Lille University Hospital * patient affiliated to "french social security" Exclusion Criteria: * pregnant woman * no consent * no affiliation to * patient affiliated to ' * preexisting bleeding disorders

What they're measuring

Frequency of major bleeding

Timeframe: During ECMO support, up to 3 weeks after implantation

Trial details

NCT IDNCT03070912

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-31

View on ClinicalTrials.gov More Von Willebrand Diseases trials